Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Sell
28
CTXR Quote, Financials, Valuation and Earnings
Last price:
$0.70
Seasonality move
:
-15.73%
Day range:
$0.68 - $0.74
52-week range:
$0.65 - $26.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.12x
Volume:
157.3K
Avg. volume:
145K
1-year change:
-95.69%
Market cap:
$7.3M
Revenue:
--
EPS (TTM):
-$5.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CTXR
Citius Pharmaceuticals
|
-- | $0.11 | -- | -75.33% | $9.00 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CTXR
Citius Pharmaceuticals
|
$0.71 | $9.00 | $7.3M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.65 | $5.00 | $51.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.71 | -- | $27.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.19 | $1.00 | $4.1M | -- | $0.00 | 0% | 1.84x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CTXR
Citius Pharmaceuticals
|
-- | -2.327 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.541 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CTXR
Citius Pharmaceuticals
|
-- | -$11.3M | -- | -- | -- | -$4.5M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Citius Pharmaceuticals vs. Competitors
-
Which has Higher Returns CTXR or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -11511.11%. Citius Pharmaceuticals's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital CTXRCitius Pharmaceuticals-- -$1.27 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About CTXR or ATNM?
Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 203.03%. Given that Citius Pharmaceuticals has higher upside potential than Actinium Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CTXRCitius Pharmaceuticals1 1 0 ATNMActinium Pharmaceuticals2 1 0 -
Is CTXR or ATNM More Risky?
Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.
-
Which is a Better Dividend Stock CTXR or ATNM?
Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTXR or ATNM?
Citius Pharmaceuticals quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Citius Pharmaceuticals's net income of -$10.9M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTXRCitius Pharmaceuticals-- -- -- -$10.9M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns CTXR or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -49.65%. Citius Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital CTXRCitius Pharmaceuticals-- -$1.27 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About CTXR or NBY?
Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Citius Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CTXRCitius Pharmaceuticals1 1 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is CTXR or NBY More Risky?
Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock CTXR or NBY?
Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTXR or NBY?
Citius Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Pharmaceuticals's net income of -$10.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTXRCitius Pharmaceuticals-- -- -- -$10.9M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns CTXR or NNVC?
Nanoviricides has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTXRCitius Pharmaceuticals-- -$1.27 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About CTXR or NNVC?
Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 280.12%. Given that Citius Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe Citius Pharmaceuticals is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings CTXRCitius Pharmaceuticals1 1 0 NNVCNanoviricides0 0 0 -
Is CTXR or NNVC More Risky?
Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock CTXR or NNVC?
Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTXR or NNVC?
Citius Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Nanoviricides's net income of -$2.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTXRCitius Pharmaceuticals-- -- -- -$10.9M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns CTXR or OGEN?
Oragenics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTXRCitius Pharmaceuticals-- -$1.27 -- OGENOragenics-- -$0.12 -- -
What do Analysts Say About CTXR or OGEN?
Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Citius Pharmaceuticals has higher upside potential than Oragenics, analysts believe Citius Pharmaceuticals is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings CTXRCitius Pharmaceuticals1 1 0 OGENOragenics0 1 0 -
Is CTXR or OGEN More Risky?
Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock CTXR or OGEN?
Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTXR or OGEN?
Citius Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Oragenics's net income of -$2.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTXRCitius Pharmaceuticals-- -- -- -$10.9M OGENOragenics1.84x -- -- -$2.2M
-
Which has Higher Returns CTXR or TOVX?
Theriva Biologics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTXRCitius Pharmaceuticals-- -$1.27 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About CTXR or TOVX?
Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Citius Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Citius Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CTXRCitius Pharmaceuticals1 1 0 TOVXTheriva Biologics1 1 0 -
Is CTXR or TOVX More Risky?
Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock CTXR or TOVX?
Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTXR or TOVX?
Citius Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTXRCitius Pharmaceuticals-- -- -- -$10.9M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 28
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
